Brookline Capital Management Predicts MRKR FY2026 Earnings

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Equities research analysts at Brookline Capital Management issued their FY2026 earnings per share estimates for Marker Therapeutics in a report issued on Monday, March 31st. Brookline Capital Management analyst L. Cann forecasts that the company will earn ($5.15) per share for the year. Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.65) per share. Brookline Capital Management also issued estimates for Marker Therapeutics’ FY2027 earnings at ($2.46) EPS, FY2028 earnings at $2.42 EPS and FY2029 earnings at $8.75 EPS.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings results on Monday, March 31st. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). Marker Therapeutics had a negative net margin of 179.74% and a negative return on equity of 89.63%. The company had revenue of $1.22 million during the quarter, compared to the consensus estimate of $5.25 million.

MRKR has been the subject of a number of other research reports. WBB Securities restated a “strong-buy” rating and issued a $12.50 price objective on shares of Marker Therapeutics in a research report on Tuesday. Canaccord Genuity Group assumed coverage on Marker Therapeutics in a report on Wednesday, March 5th. They issued a “buy” rating and a $8.00 price target for the company.

Marker Therapeutics Trading Down 7.3 %

MRKR opened at $1.14 on Wednesday. The firm’s fifty day moving average is $1.59 and its two-hundred day moving average is $2.71. Marker Therapeutics has a twelve month low of $1.10 and a twelve month high of $5.99.

Institutional Investors Weigh In On Marker Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. NEA Management Company LLC boosted its stake in Marker Therapeutics by 51.7% in the 4th quarter. NEA Management Company LLC now owns 1,625,678 shares of the company’s stock worth $5,056,000 after purchasing an additional 554,250 shares during the period. Alyeska Investment Group L.P. bought a new stake in shares of Marker Therapeutics in the fourth quarter valued at about $2,847,000. Blue Owl Capital Holdings LP acquired a new position in shares of Marker Therapeutics during the fourth quarter worth about $1,724,000. Aisling Capital Management LP grew its holdings in shares of Marker Therapeutics by 3.5% during the fourth quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock worth $1,012,000 after buying an additional 11,084 shares in the last quarter. Finally, LPL Financial LLC bought a new position in shares of Marker Therapeutics during the fourth quarter worth about $248,000. 22.39% of the stock is currently owned by institutional investors and hedge funds.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.